Drug intelligence / Profile preview

Yangyin Shugan Granules

Development stage: Unknown
Lead developer: Guangzhou Pharmaceutical Research Institute
Administration: Oral

Overview

Yangyin Shugan Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Guangzhou Pharmaceutical Research Institute for the treatment of premature ovarian insufficiency (POI). Based on TCM principles, the drug is designed to address the pattern of kidney deficiency and liver depression (肾虚肝郁). It is currently being investigated in Phase II clinical trials to evaluate its efficacy and safety in restoring ovarian function and managing symptoms in women with POI. As a botanical product, it likely exerts its effects through a multi-component, multi-target mechanism involving the regulation of the hypothalamic-pituitary-ovarian axis and the reduction of oxidative stress in ovarian tissues.

Other names: Yangyin Shugan Keli养阴疏肝颗粒

Beyond the preview

Go deeper on Yangyin Shugan Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangyin Shugan Granules.

Explore the full profile